Companies ›Healthcare ›STXS.L

STXS.L — London Stock Exchange Advanced Medical Equipment & Technology

Shield Therapeutics PLC

$6,95

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-20,2 %

ROE

117,1 %

Net margin

-35,5 %

Debt / equity

-2,00

Beta

—

52w range

—

Volume

569

Day range

$2,04–$2,09

Prev close

$2,08

Open

$2,08

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

STXS.L operates in the pharmaceuticals industry, focusing on the development and commercialization of innovative therapies for oncology and autoimmune diseases.

Business. STXS.L is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through the sale of products and is primarily listed on the London Stock Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level without further operational breakdown.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

BUY3 analysts

3 buy0 hold0 sell

Avg 12m price target17,33

Analyst recommendations

3 analysts · consensus Buy

Buy3

Hold0

Sell0

12-month price target

17,33

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

3 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

117,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning STXS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to STXS.L. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

STXS.L is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through the sale of products and is primarily listed on the London Stock Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level without further operational breakdown.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

The company's capital structure is highly leveraged, with total liabilities of $80.29 million and total equity of -$15.08 million, resulting in a negative debt-to-equity ratio of -2.0. Liquidity is constrained, as evidenced by a current ratio of 0.9, indicating that the company's current assets are insufficient to cover its current liabilities. The negative free cash flow of -$16.84 million and operating cash flow of -$3.38 million further highlight the company's liquidity challenges.

Profitability is weak, with a net loss of $17.66 million and an operating loss of $10.05 million. The return on equity of 1.171 is significantly below industry norms, and the return on assets of -0.2707 indicates that the company is not generating returns that cover its cost of capital. Gross profit of $23.04 million is insufficient to offset operating expenses, contributing to the company's unprofitable position.

The company's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or segment concentration risks. However, the lack of detailed segment reporting suggests that the company may be heavily reliant on a few key products or markets, which could increase its vulnerability to market fluctuations.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The negative operating and net income, combined with the lack of positive cash flow, suggest that the company is not currently in a position to sustain growth without external financing or operational improvements.

The company faces significant financial risks, including liquidity constraints and a negative equity position. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a key flag. The company may need to issue additional shares or secure debt financing to address its liquidity needs, which could lead to dilution for existing shareholders.

Recent events and filings do not provide specific details on the company's strategic initiatives or financial developments. However, the company's financial performance and liquidity position suggest that it may be under pressure to improve its operational efficiency or seek alternative funding sources to support its operations.

Key takeaways

The company is operating at a net loss with a negative equity position, indicating significant financial distress.
Liquidity is constrained, with a current ratio of 0.9 and negative free cash flow.
Profitability metrics are weak, with a negative return on assets and a low return on equity.
The company's growth trajectory is uncertain, and there are no specific revenue growth projections available.
The company faces liquidity risks and may need to seek additional financing to sustain operations.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$6,95

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

-$15.1M

Net cashⓘ

-$30.1M

Current ratioⓘ

0.9

Debt / equityⓘ

-2.0

ROAⓘ

-27.1%

ROEⓘ

1.2%

Cash conversionⓘ

19.0%

CapEx / revenueⓘ

-0.6%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries2

EX21:ad5736686512EX21:ad5736686512Subsidiarie97%Source ↗

EX21:fed4d79e0236EX21:fed4d79e0236Subsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs STXS · multiples and returns

TMO—

Thermo Fisher Scientific Inc

$574,03

214,1B USD

P/E

29,4x

— vs self

Div yield

0,3 %

— vs self

ROE

12,9 %

+128,5 vs self

DHR—

Danaher Corp

$197,50

140,1B USD

P/E

38,2x

— vs self

Div yield

—

— vs self

ROE

6,9 %

+122,5 vs self

GEHC—

GE HEALTHCARE TECHNOLOGIES INC.

$69,72

31,9B USD

P/E

13,6x

— vs self

Div yield

0,2 %

— vs self

ROE

19,5 %

+135,2 vs self

PHG—

PHG

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BSX—

Boston Scientific Corp

$48,54

72,6B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

ISRG—

INTUITIVE SURGICAL, INC.

$376,00

133,2B USD

P/E

287,7x

— vs self

Div yield

—

— vs self

ROE

3,6 %

+119,2 vs self

A—

Agilent Technologies Inc

$139,80

39,6B USD

P/E

29,0x

— vs self

Div yield

0,8 %

— vs self

ROE

19,3 %

+134,9 vs self

EW—

Edwards Lifesciences Corp

$88,82

51,6B USD

P/E

44,3x

— vs self

Div yield

—

— vs self

ROE

10,4 %

+126,0 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,00

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-10 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,00
Revenue	—no estimate	—no estimate	76,0M USD
Operating income	—no estimate	—no estimate	4,2M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution3 analysts

Strong buy2

Buy1

Hold0

Sell0

Strong sell0

12-month price target$17,33 · Median $15,00

Low $14,00High $23,00

Operating income · consensus4,2M USD

EPS surprise

−1 900,0 %

reported vs consensus · miss

Revenue surprise

−34,6 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$14,00

Mean$17,33

Median$15,00

High$23,00

Spot$6,95

+149.4 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-20,2 %Below median

Net Margin-35,5 %Below median

ROE117,1 %Best in class

Capex / Rev-0,6 %Above P75

D/E-2,00Best in class

Cash Conv0,19Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 40 000 sh1 grants1 insiders

Peery Kimberly R.Chief Financial Officer · Stock Options -Right to Buy → Common StockAcquired 40 000 @ $1,87grant · 2026-04-11

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

STXS.L Market data — financials · 2026-05-29
Shield Therapeutics PLC Market data — analyst estimates · 2026-05-29

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$3M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$6M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$8M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$2M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

David Leo FischelChairman of the Board, Chief Executive Officer

Insider activity

Net buying2 buys · 0 sellsnet $67K7 insiders · last 365d

Levin Ross BDirector · Common StockOther 46 948 · 2026-01-02
Menawat Arun SwarupDirector · Common StockOther 46 948 · 2026-01-02
Benfer DavidDirector · Common StockOther 46 948 · 2026-01-02
Curet MyriamDirector · Common StockOther 46 948 · 2026-01-02
Fischel NathanDirector, 10% owner · Common StockOther 46 948 · 2026-01-02
SHAMIR NACHUMDirector · Common StockOther 46 948 · 2026-01-02
Isaac Paul JDirector, See Remarks · Common StockBought 10 000 @ $2,18$22K · 2025-11-17
Isaac Paul JDirector, See Remarks · Common StockBought 20 000 @ $2,24$45K · 2025-11-14

Short positioning

4.5Mshares short+4.6% vs prior

6.67days to cover

60.5%short of daily vol

22.9Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

STXS.LCanonical

London Stock Exchange · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -61.1%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 9.9%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 24.2%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -5.0%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 11.8%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 121.7%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 20.3%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -3.9%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 10.6%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 10.0%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 17.0%Derived (calculated)
Net margin (FY 2025-12-31): -66.8%Derived (calculated)
Gross margin (FY 2025-12-31): 52.7%Derived (calculated)
Return on equity (FY 2025-12-31): -160.5%Derived (calculated)
Return on assets (FY 2025-12-31): -41.4%Derived (calculated)
Current ratio (FY 2025-12-31): 1.51xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 2.49xDerived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
R&D expense (annual): USD 9.38MSEC XBRL filing
Operating income (annual): USD -22.11MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
Gross profit (annual): USD 17.07MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-05-15FILING8-K filing →

2026-05-13FILING10-Q filing →

2026-05-12FILING8-K filing →

2026-04-15FILING8-K filing →

2026-04-11 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative

2026-04-11INSIDERPeery Kimberly R. acquired 40.0k sh Stock Options -Right to Buy — Chief Financial Officer

2026-04-03FILINGDEF 14A filing →

2026-03-12FILING10-K filing →

2026-03-09FILING8-K filing →

2026-01-02 00:00 UTCINSIDER6 insider transactions — 2026-01

2026-01-02INSIDERLevin Ross B transacted 46.9k sh — Director

2026-01-02INSIDERMenawat Arun Swarup transacted 46.9k sh — Director

2026-01-02INSIDERBenfer David transacted 46.9k sh — Director

2026-01-02INSIDERCuret Myriam transacted 46.9k sh — Director

2026-01-02INSIDERFischel Nathan transacted 46.9k sh — Director, 10% owner

2026-01-02INSIDERSHAMIR NACHUM transacted 46.9k sh — Director

2025-11-17 00:00 UTCINSIDER2 insider transactions — 2025-11

2025-11-17INSIDERIsaac Paul J bought 10.0k sh — Director, See Remarks ~$22k

2025-11-14INSIDERIsaac Paul J bought 20.0k sh — Director, See Remarks ~$45k

2025-11-12FILING10-Q filing →

2025-11-12FILING8-K filing →

2025-08-29FILING424B5 filing →

2025-08-29FILING8-K filing →

2025-08-13FILING10-Q filing →

2025-07-01 00:00 UTCINSIDER6 insider transactions — 2025-07

2025-04-08 00:00 UTCINSIDER1 insider transaction — 2025-04 1 derivative

2025-03-10 00:00 UTCINSIDER3 insider transactions — 2025-03 · net buy $114k

2025-01-02 00:00 UTCINSIDER6 insider transactions — 2025-01

2024-08-20 00:00 UTCINSIDER3 insider transactions — 2024-08

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread